Quince Therapeutics, Inc. 8-K

What Happened

• Quince Therapeutics, Inc. (QNCX) filed an 8-K on April 9, 2026 reporting that its board filed a Certificate of Amendment to effect a 1-for-10 reverse stock split. The amendment becomes effective at 11:59 p.m. Eastern on April 10, 2026, and the company’s common stock will begin trading on a split-adjusted basis on the Nasdaq Global Select Market at market open on April 13, 2026.

Key Details

• Reverse ratio: 1-for-10 (every ten shares combined into one share).
• Shares outstanding after split: approximately 16,300,795 common shares. (Pre-split outstanding would be roughly 163,007,950.)
• Ticker and CUSIP: Shares will continue to trade under the symbol "QNCX" with a new CUSIP 22053A206 effective April 13, 2026.
• Fractional shares: Stockholders who would otherwise receive fractional shares will receive cash in lieu of fractional shares.
• Other effects: The reverse split does not change the rights or preferences of the common stock; outstanding stock options and warrants will be proportionally adjusted.
• Exchange agent/transfer agent: Equiniti Trust Company, LLC appointed to act as exchange agent. Shares held through brokers/nominees will be adjusted automatically per broker procedures.

Why It Matters

• The reverse split reduces the number of outstanding shares and increases the per-share price proportionally, but does not change any stockholder’s percentage ownership (except for cash-outs of fractional shares).
• For investors this means share counts on brokerage statements and option/warrant strike/quantity will be adjusted; no action is generally required for shareholders holding through a broker.
• The company retains the same ticker (QNCX) but will trade under a new CUSIP, so investors should see the change reflected on or after the April 13, 2026 market open.